Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Junshi Announces $1.1 Billion Agreement for US-Canada Rights to PD-1

publication date: Feb 1, 2021

Shanghai Junshi Bio out-licensed US-Canada rights for its anti-PD-1 antibody to Coherus Bio in an agreement worth up to $1.1 billion. Coherus will pay $150 million upfront. Coherus also received options for an anti-TIGIT antibody and a next-gen engineered IL-2 cytokine, as well as first negotiation rights for two early-stage checkpoint inhibitor antibodies. Junshi's Tuoyi (toripalimab) is the first China-developed anti-PD-1 antibody approved in China. More details....

Stock Symbols: (HK: 1877; SHA: 688180) (NSDQ: CHRS)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.